

DuPont de Nemours, Inc. ("DuPont" or the "Company")
Reconciliation of non-GAAP financial measures and other supplemental information

This presentation includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the following tables. Non-GAAP measures included in this release are defined as follows:

Pro forma adjusted earnings per common share from continuing operations - diluted ("Pro forma adjusted EPS"), is defined as pro forma earnings per common share from continuing operations - diluted, excluding the after-tax impact of significant items, after-tax impact of amortization expense associated with intangibles acquired as part of the Merger, after-tax impact of non-operating pension / other post employment benefits ("OPEB") benefits / charges and the after-tax impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations. Adjusted earnings per common share from continuing operations - diluted ("Adjusted EPS"), is defined as earnings per common share from continuing operations - diluted, excluding the after-tax impact of significant items, after-tax impact of amortization expense associated with intangibles acquired as part of the Merger and the after-tax impact of non-operating pension / other post employment benefits ("OPEB") benefits / charges. Although amortization of Historical EID intangibles acquired as part of the Merger is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets.

Pro forma operating EBITDA, is defined as earnings (i.e. pro forma income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted to exclude significant items. Operating EBITDA, is defined as earnings (i.e. income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted to exclude significant items.

Significant items are items that arise outside the ordinary course of the Company's business that management believes may cause misinterpretation of underlying business performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance.

Free cash flow is defined as cash provided by/used for operating activities less capital expenditures. As a result, free cash flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities. Management believes free cash flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Free cash flow conversion is defined as free cash flow divided by net income adjusted to exclude non-cash impairment charges, gains or losses on divestitures, and after-tax Historical EID merger-related amortization.

Unaudited Pro Forma Financial Information

The unaudited pro forma financial information (the "pro forma financial statements") is derived from DuPont's Consolidated Financial Statements and accompanying notes, adjusted to give effect to certain events directly attributable to the Distributions and Financings (as defined below). In contemplation of the Distributions and to achieve the respective credit profiles of each of DuPont, Dow, and Corteva, in the fourth quarter of 2018, DowDuPont consummated a public underwritten offer of eight series of senior unsecured notes (the "2018 Senior Notes") in the aggregate principal amount of \$12.7 billion and entered into a term loan agreement consisting of two term loan facilities (the "Term Loan Facilities") in the aggregate principal amount of \$3.0 billion. In May 2019, the funds from the Term Loan Facilities were drawn, along with the issuance of approximately \$1.4 billion in commercial paper (the "Funding CP Issuance" together with the 2018 Senior Notes and Term Loan Facilities, the "Financings"). The net proceeds from the Financings together with cash from operations were used to fund cash contributions to Dow and Corteva, and DowDuPont's \$3.0 billion share repurchase program which was completed in the first quarter of 2019 (the "Share Repurchase Program").

The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the Consolidated Statements of Operations, expected to have a continuing impact on the results. The unaudited pro forma Consolidated Statements of Operations for the year ended December 31, 2019, the three months ended March 31, 2019 and all periods in 2018 and 2017 give effect to the pro forma events as if they had been consummated on January 1, 2017. There were no pro forma adjustments for the three months ended September 30, 2020, June 30, 2020, March 31, 2020, December 31, 2019, September 30, 2019 and June 30, 2019.

Restructuring or integration activities or other costs following the Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The pro forma financial statements provide shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.

The pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.

DuPont de Nemours, Inc.
Selected Non-GAAP Calculation of Operating EBITDA (Unaudited)

<i>In millions</i>	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>Pro Forma</i>	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>
(Loss) Income from continuing operations, net of tax (GAAP)	\$ (3,153)	\$ (72)	\$ (2,471)	\$ (610)	\$ (522)	\$ 191	\$ 372	\$ (1,103)	\$ 18	\$ 237	\$ 310	\$ 88	\$ (11)	\$ (150)	\$ 450
Provision (Credit) for income taxes	100	92	(36)	44	170	(2)	78	155	(61)	153	(4)	24	89	44	(2,295)
(Loss) Income from continuing operations before income taxes	\$ (3,053)	\$ 20	\$ (2,507)	\$ (566)	\$ (352)	\$ 189	\$ 450	\$ (948)	\$ (43)	\$ 390	\$ 306	\$ 112	\$ 78	\$ (106)	\$ (1,845)
+ Depreciation and Amortization	2,326	780	774	772	2,066	533	499	507	527	2,170	526	542	551	551	2,131
- Interest income	7	3	2	2	55	5	1	9	40	39	10	8	11	10	22
+ Interest expense	519	165	181	173	697	175	177	165	180	684	171	171	171	171	684
- Non-operating pension/OPEB benefit	24	5	8	11	74	14	21	18	21	96	17	24	28	27	57
- Foreign exchange gains (losses), net	(41)	(10)	(23)	(8)	(110)	(9)	(23)	(17)	(61)	(43)	55	(26)	53	(125)	(493)
+ Costs historically allocated to the materials science and agriculture businesses ¹	-	-	-	-	256	-	-	-	256	1,044	202	234	352	256	1,192
- Adjustments for significant items (charge)	(3,954)	(333)	(2,674)	(947)	(2,992)	(500)	(274)	(1,708)	(510)	(1,709)	(499)	(402)	(362)	(446)	(2,593)
Operating EBITDA (non-GAAP)	\$ 3,756	\$ 1,300	\$ 1,135	\$ 1,321	\$ 5,640	\$ 1,387	\$ 1,401	\$ 1,422	\$ 1,430	\$ 5,905	\$ 1,622	\$ 1,455	\$ 1,422	\$ 1,406	\$ 5,169

1. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

DuPont de Nemours, Inc.

Pretax Non-GAAP Adjustments to Net Income (Unaudited)

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
(Loss) income from continuing operations before income taxes (GAAP) ¹	\$ (3,053)	\$ 20	\$ (2,507)	\$ (566)	\$ (352)	\$ 189	\$ 450	\$ (948)	\$ (43)	\$ 390	\$ 306	\$ 112	\$ 78	\$ (106)	\$ (1,845)
Less: Significant items (charge), before tax ¹	(3,954)	(333)	(2,674)	(947)	(2,992)	(500)	(274)	(1,708)	(510)	(1,709)	(499)	(402)	(362)	(446)	(2,593)
Less: Merger-related amortization of intangibles, before tax ¹	(1,438)	(482)	(474)	(482)	(845)	(247)	(199)	(199)	(200)	(817)	(200)	(202)	(207)	(208)	(774)
Less: Non-op pension / OPEB benefit, before tax ¹	24	5	8	11	74	14	21	18	21	96	17	24	28	27	57
Less: Costs historically allocated to the materials science and agriculture businesses before tax ¹	-	-	-	-	(256)	-	-	-	(256)	(1,044)	(202)	(234)	(352)	(256)	(1,192)
Adjusted results, before tax (non-GAAP)	\$ 2,315	\$ 830	\$ 633	\$ 852	\$ 3,667	\$ 922	\$ 902	\$ 941	\$ 902	\$ 3,864	\$ 1,190	\$ 926	\$ 971	\$ 777	\$ 2,657

1. Impact on (loss) income from continuing operations before income tax.

Pretax Significant Items (Unaudited)

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Merger-related inventory step-up amortization ¹	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (77)	\$ (4)	\$ -	\$ (4)	\$ (69)	\$ (1,355)
Net gain (loss) on divestitures and changes in joint venture ownership ²	590	393	-	197	-	-	-	-	-	(41)	(14)	(6)	(21)	-	162
Integration and separation costs ³	(469)	(127)	(145)	(197)	(1,169)	(193)	(191)	(347)	(438)	(1,394)	(444)	(385)	(291)	(274)	(810)
Restructuring and asset-related (charges) credits - net ⁴	(146)	(14)	2	(134)	(255)	(25)	(83)	(75)	(72)	(147)	(37)	(11)	(46)	(53)	(519)
Goodwill impairment charge	(3,214)	(183)	(2,498)	(533)	(1,175)	-	-	(1,175)	-	-	-	-	-	-	-
Asset impairment charge	(661)	(370)	(21)	(270)	(63)	-	-	(63)	-	-	-	-	-	-	(71)
N&B financing activities - net	(54)	(32)	(12)	(10)	-	-	-	-	-	-	-	-	-	-	-
Net charge related to a joint venture ⁵	-	-	-	-	(208)	(208)	-	-	-	-	-	-	-	-	-
Income tax related item	-	-	-	-	(122)	(74)	-	(48)	-	(50)	-	-	-	(50)	-
Total pretax significant items (charge) benefit	\$ (3,954)	\$ (333)	\$ (2,674)	\$ (947)	\$ (2,992)	\$ (500)	\$ (274)	\$ (1,708)	\$ (510)	\$ (1,709)	\$ (499)	\$ (402)	\$ (362)	\$ (446)	\$ (2,593)

1. Reflected in cost of sales.

2. Reflected in sundry income (expense) - net.

3. Integration and separation costs related to the Merger, post-Merger integration, the Distributions and beginning in the fourth quarter 2019 the intended separation of the Nutrition & Biosciences business.

4. Includes Board approved restructuring plans and asset related charges.

5. Reflects the Company's share of net charges related to a joint venture in the Non-Core segment.

Non-GAAP Adjustments to Net Income (Unaudited)

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Net (loss) income from continuing operations available to DuPont common stockholders (GAAP) ¹	\$ (3,173)	\$ (79)	\$ (2,478)	\$ (616)	\$ (552)	\$ 179	\$ 367	\$ (1,112)	\$ 14	\$ 198	\$ 297	\$ 73	\$ (9)	\$ (163)	\$ 419
Less: Significant items benefit (charge), net of tax ¹	(3,866)	(359)	(2,634)	(873)	(2,596)	(346)	(212)	(1,700)	(338)	(1,596)	(502)	(332)	(292)	(470)	(600)
Less: Merger-related amortization of intangibles, net of tax ¹	(1,101)	(369)	(364)	(368)	(660)	(191)	(155)	(157)	(157)	(641)	(157)	(158)	(163)	(163)	(533)
Less: Non-op pension / OPEB benefit, net of tax ¹	18	4	6	8	67	12	18	20	17	80	16	20	22	22	42
Less: Costs historically allocated to the materials science and agriculture businesses net of tax ¹	-	-	-	-	(197)	-	-	-	(197)	(804)	(156)	(180)	(271)	(197)	(763)
Adjusted results, net of tax (non-GAAP)	\$ 1,776	\$ 645	\$ 514	\$ 617	\$ 2,834	\$ 704	\$ 716	\$ 725	\$ 689	\$ 3,159	\$ 1,096	\$ 723	\$ 695	\$ 645	\$ 2,273

1. Impact on (loss) income from continuing operations, net of tax. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible.

Significant Items, net of tax (Unaudited)

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Merger-related inventory step-up amortization ¹	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (66)	\$ (4)	\$ -	\$ (1)	\$ (61)	\$ (1,068)
Net gain (loss) on divestitures and changes in joint venture ownership ²	334	232	-	102	-	-	-	-	-	(36)	(14)	(6)	(16)	-	86
Integration and separation costs ³	(363)	(97)	(112)	(154)	(895)	(148)	(147)	(255)	(345)	(1,158)	(369)	(330)	(237)	(222)	(558)
Restructuring and asset-related (charges) credits - net ⁴	(113)	(12)	1	(102)	(195)	(17)	(65)	(58)	(55)	(121)	(36)	(5)	(38)	(42)	(351)
Goodwill impairment charge	(3,214)	(183)	(2,498)	(533)	(1,173)	-	-	(1,173)	-	-	-	-	-	-	-
Asset impairment charge	(503)	(281)	(16)	(206)	(47)	-	-	(47)	-	-	-	-	-	-	(48)
N&B financing activities - net	(41)	(24)	(9)	(8)	-	-	-	-	-	(8)	-	-	-	-	-
Net charge related to a joint venture ⁵	-	-	-	-	(158)	(158)	-	-	-	-	-	-	-	-	-
Income tax related item	34	6	-	28	(128)	(23)	-	(167)	62	(215)	(79)	9	-	(145)	1,339
Total pretax significant items (charge) benefit, net of tax ⁶	\$ (3,866)	\$ (359)	\$ (2,634)	\$ (873)	\$ (2,596)	\$ (346)	\$ (212)	\$ (1,700)	\$ (338)	\$ (1,596)	\$ (502)	\$ (332)	\$ (292)	\$ (470)	\$ (600)

1. Reflected in cost of sales.

2. Reflected in sundry income (expense) - net.

3. Integration and separation costs related to the Merger, post-Merger integration, the Distributions and beginning in the fourth quarter of 2019, the intended separation of the Nutrition & Biosciences business.

4. Includes Board approved restructuring plans and asset related charges.

5. Reflects the Company's share of net charges related to a joint venture in the Non-Core segment.

6. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible.

DuPont de Nemours, Inc.
Non-GAAP Adjustments to Earnings Per Share (Unaudited)

In millions	YTD 2020 ¹	2020			YTD 2019 ¹	2019				YTD 2018 ¹	2018				YTD 2017 ¹
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
(Loss) Earnings per common share from continuing operations - diluted (GAAP) ²	\$ (4.31)	\$ (0.11)	\$ (3.37)	\$ (0.83)	\$ (0.74)	\$ 0.24	\$ 0.49	\$ (1.48)	\$ 0.02	\$ 0.23	\$ 0.39	\$ 0.09	\$ (0.02)	\$ (0.22)	\$ 0.52
Less: Significant items (charge) benefit - diluted ²	(5.25)	(0.49)	(3.59)	(1.18)	(3.48)	(0.47)	(0.28)	(2.27)	(0.45)	(2.07)	(0.66)	(0.43)	(0.38)	(0.61)	(0.77)
Less: Merger-related amortization of intangibles - diluted ²	(1.49)	(0.50)	(0.49)	(0.50)	(0.88)	(0.26)	(0.21)	(0.21)	(0.21)	(0.83)	(0.21)	(0.21)	(0.21)	(0.21)	(0.68)
Less: Non-op pension / OPEB benefit - diluted ²	0.02	-	0.01	0.01	0.08	0.02	0.02	0.03	0.02	0.10	0.03	0.03	0.03	0.03	0.05
Less: Costs historically allocated to the materials science and agriculture businesses - diluted ²	-	-	-	-	(0.26)	-	-	-	(0.26)	(1.04)	(0.20)	(0.24)	(0.35)	(0.26)	(0.97)
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 2.41	\$ 0.88	\$ 0.70	\$ 0.84	\$ 3.80	\$ 0.95	\$ 0.96	\$ 0.97	\$ 0.92	\$ 4.07	\$ 1.43	\$ 0.94	\$ 0.89	\$ 0.83	\$ 2.89

1. (Loss) Earnings per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly (loss) earnings per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Impact on earnings per common share from continuing operations - diluted

Significant Items Earnings Per Share (Unaudited)

In millions	YTD 2020 ¹	2020			YTD 2019 ¹	2019				YTD 2018 ¹	2018				YTD 2017 ¹
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Merger-related inventory step-up amortization ²	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.09)	\$ (0.01)	\$ -	\$ (0.00)	\$ (0.08)	\$ (1.37)
Net gain (loss) on divestitures and changes in joint venture ownership ³	0.45	0.32	-	0.14	-	-	-	-	-	(0.05)	(0.02)	(0.01)	(0.02)	-	0.11
Integration and separation costs ⁴	(0.49)	(0.13)	(0.16)	(0.21)	(1.21)	(0.21)	(0.19)	(0.34)	(0.46)	(1.49)	(0.48)	(0.42)	(0.31)	(0.29)	(0.71)
Restructuring and asset-related charges - net ⁵	(0.15)	(0.02)	-	(0.14)	(0.26)	(0.02)	(0.09)	(0.08)	(0.07)	(0.16)	(0.05)	(0.01)	(0.05)	(0.05)	(0.45)
Goodwill impairment charge	(4.37)	(0.25)	(3.40)	(0.72)	(1.57)	-	-	(1.57)	-	-	-	-	-	-	-
Asset impairment charge	(0.68)	(0.38)	(0.02)	(0.28)	(0.06)	-	-	(0.06)	-	-	-	-	-	-	(0.06)
N&B financing activities - net	(0.06)	(0.04)	(0.01)	(0.01)	-	-	-	-	-	-	-	-	-	-	-
Net charge related to a joint venture ⁶	-	-	-	-	(0.21)	(0.21)	-	-	-	-	-	-	-	-	-
Income tax related item	0.05	0.01	-	0.04	(0.17)	(0.03)	-	(0.22)	0.08	(0.28)	(0.10)	0.01	-	(0.19)	1.71
Total significant items (charge) benefit - diluted	\$ (5.25)	\$ (0.49)	\$ (3.59)	\$ (1.18)	\$ (3.48)	\$ (0.47)	\$ (0.28)	\$ (2.27)	\$ (0.45)	\$ (2.07)	\$ (0.66)	\$ (0.43)	\$ (0.38)	\$ (0.61)	\$ (0.77)

1. (Loss) Earnings per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly (loss) earnings per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Reflected in cost of sales.

3. Reflected in sundry income (expense) - net.

4. Integration and separation costs related to the Merger, post-Merger integration, the Distributions and the beginning in the fourth quarter of 2019, the intended separation of the Nutrition & Biosciences business.

5. Includes Board approved restructuring plans and asset related charges, which include other asset impairments.

6. Reflects the Company's share of net charges related to joint venture in the Non-Core segment.

DuPont de Nemours, Inc.
Selected Segment Information (Unaudited)

Net Sales

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Electronics & Imaging	\$ 2,793	\$ 1,004	\$ 905	\$ 884	\$ 3,554	\$ 937	\$ 934	\$ 858	\$ 825	\$ 3,635	\$ 910	\$ 940	\$ 921	\$ 864	\$ 3,592
Nutrition & Biosciences	4,557	1,467	1,539	1,551	6,076	1,458	1,525	1,558	1,535	6,216	1,485	1,533	1,621	1,577	5,389
Transportation & Industrial	3,021	1,045	832	1,144	4,950	1,155	1,209	1,269	1,317	5,422	1,270	1,357	1,417	1,378	4,958
Safety & Construction	3,769	1,249	1,244	1,276	5,201	1,250	1,327	1,341	1,283	5,294	1,294	1,364	1,372	1,264	5,003
Non-Core	1,005	331	308	366	1,731	404	431	442	454	2,027	498	489	526	514	2,058
Total net sales by segment	\$ 15,145	\$ 5,096	\$ 4,828	\$ 5,221	\$ 21,512	\$ 5,204	\$ 5,426	\$ 5,468	\$ 5,414	\$ 22,594	\$ 5,457	\$ 5,683	\$ 5,857	\$ 5,597	\$ 21,000
Less: Non-Core	1,005	331	308	366	1,731	404	431	442	454	2,027	498	489	526	514	2,058
Total net sales of core segments (non-GAAP)	\$ 14,140	\$ 4,765	\$ 4,520	\$ 4,855	\$ 19,781	\$ 4,800	\$ 4,995	\$ 5,026	\$ 4,960	\$ 20,567	\$ 4,959	\$ 5,194	\$ 5,331	\$ 5,083	\$ 18,942

Operating EBITDA

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Electronics & Imaging	\$ 887	\$ 357	\$ 277	\$ 253	\$ 1,147	\$ 293	\$ 320	\$ 246	\$ 288	\$ 1,210	\$ 321	\$ 322	\$ 290	\$ 277	\$ 1,190
Nutrition & Biosciences	1,182	379	418	385	1,406	317	354	386	349	1,420	323	357	378	362	1,143
Transportation & Industrial	599	242	49	308	1,313	277	306	357	373	1,518	344	383	402	389	1,235
Safety & Construction	1,041	324	349	368	1,419	311	352	382	374	1,283	311	350	296	326	1,178
Non-Core	149	14	93	42	512	216	94	104	98	702	365	93	128	116	680
Corporate	(102)	(16)	(51)	(35)	(157)	(27)	(25)	(53)	(52)	(228)	(42)	(50)	(72)	(64)	(257)
Total operating EBITDA (non-GAAP)	\$ 3,756	\$ 1,300	\$ 1,135	\$ 1,321	\$ 5,640	\$ 1,387	\$ 1,401	\$ 1,422	\$ 1,430	\$ 5,905	\$ 1,622	\$ 1,455	\$ 1,422	\$ 1,406	\$ 5,169
Less: Non-Core	149	14	93	42	512	216	94	104	98	702	365	93	128	116	680
Total operating EBITDA of core segments (non-GAAP)	\$ 3,607	\$ 1,286	\$ 1,042	\$ 1,279	\$ 5,128	\$ 1,171	\$ 1,307	\$ 1,318	\$ 1,332	\$ 5,203	\$ 1,257	\$ 1,362	\$ 1,294	\$ 1,290	\$ 4,489

Operating EBITDA Margin

In millions	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18	YTD 2017
	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Electronics & Imaging	31.8%	35.6%	30.6%	28.6%	32.3%	31.3%	34.3%	28.7%	34.9%	33.3%	35.3%	34.3%	31.5%	32.1%	33.1%
Nutrition & Biosciences	25.9%	25.8%	27.2%	24.8%	23.1%	21.7%	23.2%	24.8%	22.7%	22.8%	21.8%	23.3%	23.3%	23.0%	21.2%
Transportation & Industrial	19.8%	23.2%	5.9%	26.9%	26.5%	24.0%	25.3%	28.1%	28.3%	28.0%	27.1%	28.2%	28.4%	28.2%	24.9%
Safety & Construction	27.6%	25.9%	28.1%	28.8%	27.3%	24.9%	26.5%	28.5%	29.2%	24.2%	24.0%	25.7%	21.6%	25.8%	23.5%
Non-Core	14.8%	4.2%	30.2%	11.5%	29.6%	53.5%	21.8%	23.5%	21.6%	34.6%	73.3%	19.0%	24.3%	22.6%	33.0%
Total operating EBITDA margin (non-GAAP)^{1,2}	24.8%	25.5%	23.5%	25.3%	26.2%	26.7%	25.8%	26.0%	26.4%	26.1%	29.7%	25.6%	24.3%	25.1%	24.6%
Less: Non-Core	14.8%	4.2%	30.2%	11.5%	29.6%	53.5%	21.8%	23.5%	21.6%	34.6%	73.3%	19.0%	24.3%	22.6%	33.0%
Total operating EBITDA margin of core segments (non-GAAP)^{1,2}	25.5%	27.0%	23.1%	26.3%	25.9%	24.4%	26.2%	26.2%	26.9%	25.3%	25.3%	26.2%	24.3%	25.4%	23.7%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales

2. Operating EBITDA Margin %s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the Total margin %s above.

DuPont de Nemours, Inc.
Selected Segment Information (Unaudited)

Significant Items (Pretax)

In millions	YTD 2020	3Q20		2Q20		1Q20		YTD 2019	4Q19		3Q19		2Q19		1Q19		YTD 2018	4Q18		3Q18		2Q18		1Q18		YTD 2017
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Electronics & Imaging	\$ 195	\$ (1)	\$ 3	\$ 193	\$ (47)	\$ (5)	\$ (35)	\$ (7)	\$ -	\$ (2)	\$ -	\$ -	\$ (1)	\$ (1)	\$ (1)	\$ (234)	\$ (2)	\$ -	\$ -	\$ -	\$ (4)	\$ (64)	\$ (231)	\$ (234)	\$ (234)	
Nutrition & Biosciences	(9)	(5)	2	(6)	(1,055)	(3)	(7)	(1,018)	(27)	(97)	(29)	-	(4)	(64)	(231)	(231)	(97)	(29)	-	(4)	(64)	(231)	(231)	(231)	(231)	
Transportation & Industrial	(2,534)	-	(2,509)	(25)	(19)	(1)	(6)	(12)	-	(2)	(3)	-	-	1	(340)	(340)	(2)	(3)	-	-	1	(340)	(340)	(340)	(340)	
Safety & Construction	(15)	(2)	12	(25)	(80)	(5)	(5)	(68)	(2)	(47)	(21)	(2)	(12)	(12)	(725)	(725)	(47)	(21)	(2)	(12)	(12)	(12)	(12)	(12)	(725)	
Non-Core	(964)	(161)	-	(803)	(454)	(210)	(2)	(243)	1	(15)	7	(7)	(16)	1	(153)	(153)	(15)	7	(7)	(16)	1	(153)	(153)	(153)	(153)	
Corporate	(627)	(164)	(182)	(281)	(1,337)	(276)	(219)	(360)	(482)	(1,546)	(453)	(393)	(329)	(371)	(910)	(910)	(1,546)	(453)	(393)	(329)	(371)	(371)	(371)	(371)	(910)	
Total significant items (charges) benefit by segment (Pretax)	\$ (3,954)	\$ (333)	\$ (2,674)	\$ (947)	\$ (2,992)	\$ (500)	\$ (274)	\$ (1,708)	\$ (510)	\$ (1,709)	\$ (499)	\$ (402)	\$ (362)	\$ (446)	\$ (2,593)	\$ (2,593)	\$ (1,709)	\$ (499)	\$ (402)	\$ (362)	\$ (446)	\$ (446)	\$ (446)	\$ (446)	\$ (446)	\$ (2,593)

Depreciation and Amortization (Pretax)

In millions	YTD 2020	3Q20		2Q20		1Q20		YTD 2019	4Q19		3Q19		2Q19		1Q19		YTD 2018	4Q18		3Q18		2Q18		1Q18		YTD 2017
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma
Electronics & Imaging	\$ 252	\$ 84	\$ 86	\$ 82	\$ 339	\$ 81	\$ 84	\$ 84	\$ 90	\$ 390	\$ 91	\$ 97	\$ 100	\$ 102	\$ 394	\$ 394	\$ 390	\$ 91	\$ 97	\$ 100	\$ 102	\$ 102	\$ 102	\$ 102	\$ 394	
Nutrition & Biosciences	1,295	438	427	430	675	205	158	155	157	643	152	160	165	166	562	562	643	152	160	165	166	166	166	166	562	
Transportation & Industrial	312	105	106	101	423	100	104	108	111	456	113	116	113	114	456	456	456	113	116	113	114	114	114	114	456	
Safety & Construction	374	124	128	122	503	118	124	127	134	549	132	138	140	139	562	562	549	132	138	140	139	139	139	139	562	
Non-Core	91	28	28	35	127	30	30	33	34	124	33	28	31	32	132	132	124	33	28	31	32	32	32	32	132	
Corporate	2	1	(1)	2	(1)	(1)	(1)	-	1	8	5	3	2	(2)	25	25	8	5	3	2	(2)	(2)	(2)	(2)	25	
Total depreciation and amortization by segment (Pretax)	\$ 2,326	\$ 780	\$ 774	\$ 772	\$ 2,066	\$ 533	\$ 499	\$ 507	\$ 527	\$ 2,170	\$ 526	\$ 542	\$ 551	\$ 551	\$ 2,131	\$ 2,131	\$ 2,170	\$ 526	\$ 542	\$ 551	\$ 551	\$ 551	\$ 551	\$ 551	\$ 2,131	

Equity Earnings

In millions	YTD 2020	3Q20		2Q20		1Q20		YTD 2019	4Q19		3Q19		2Q19		1Q19		YTD 2018	4Q18		3Q18		2Q18		1Q18		YTD 2017	
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	Pro Forma	
Equity earnings (GAAP)	\$ 172	\$ 30	\$ 103	\$ 39	\$ 84	\$ (48)	\$ 43	\$ 49	\$ 40	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 410	\$ 410	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 57	\$ 57	\$ 57	\$ 410		
Significant items included in equity earnings ¹	-	-	-	-	228	225	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Equity earnings included in operating EBITDA (non-GAAP)	\$ 172	\$ 30	\$ 103	\$ 39	\$ 312	\$ 177	\$ 44	\$ 50	\$ 41	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 410	\$ 410	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 57	\$ 57	\$ 57	\$ 410		
Equity earnings included in operating EBITDA by segment																											
Electronics & Imaging	\$ 27	\$ 8	\$ 10	\$ 9	\$ 24	\$ 6	\$ 10	\$ 5	\$ 3	\$ 23	\$ 3	\$ 7	\$ 6	\$ 7	\$ 20	\$ 20	\$ 23	\$ 3	\$ 7	\$ 6	\$ 7	\$ 7	\$ 7	\$ 7	\$ 20		
Nutrition & Biosciences	2	1	1	-	(1)	(1)	-	-	-	(1)	(2)	-	-	1	(2)	(2)	(1)	(2)	-	-	-	1	1	1	(2)		
Transportation & Industrial	3	1	1	1	4	1	1	2	-	1	(3)	1	1	2	5	5	1	(3)	1	1	2	2	2	2	5		
Safety & Construction	19	7	5	7	27	5	7	7	8	24	5	6	8	5	18	18	24	5	6	8	8	8	8	8	18		
Non-Core	121	13	86	22	258	166	26	36	30	400	288	31	39	42	369	369	400	288	31	39	42	42	42	42	369		
Total equity earnings included in operating EBITDA (non-GAAP)	\$ 172	\$ 30	\$ 103	\$ 39	\$ 312	\$ 177	\$ 44	\$ 50	\$ 41	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 410	\$ 410	\$ 447	\$ 291	\$ 45	\$ 54	\$ 57	\$ 57	\$ 57	\$ 57	\$ 410		

1. Related to a joint venture in the Non-Core segment.

DuPont de Nemours, Inc.

Supplemental Information - Selected Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

<i>In millions</i>	YTD 2020	3Q20	2Q20	1Q20	YTD 2019	4Q19	3Q19	2Q19	1Q19	YTD 2018	4Q18	3Q18	2Q18	1Q18
	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>Pro Forma</i>	<i>As Reported</i>	<i>As Reported</i>	<i>As Reported</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>	<i>Pro Forma</i>
Image Solutions	\$ 491	\$ 172	\$ 155	\$ 164	\$ 687	\$ 180	\$ 167	\$ 169	\$ 171	\$ 687	\$ 176	\$ 182	\$ 174	\$ 155
Interconnect Solutions	910	370	274	266	1,187	328	339	282	238	1,174	282	313	298	281
Semiconductor Technologies	1,392	462	476	454	1,680	429	428	407	416	1,774	452	445	449	428
Electronics & Imaging	\$ 2,793	\$ 1,004	\$ 905	\$ 884	\$ 3,554	\$ 937	\$ 934	\$ 858	\$ 825	\$ 3,635	\$ 910	\$ 940	\$ 921	\$ 864
Food & Beverage	\$ 2,163	\$ 686	\$ 739	\$ 738	\$ 2,945	\$ 708	\$ 736	\$ 746	\$ 755	\$ 2,987	\$ 727	\$ 733	\$ 783	\$ 744
Health & Biosciences	1,754	570	579	605	2,317	561	582	604	570	2,405	568	601	618	618
Pharma Solutions	640	211	221	208	814	189	207	208	210	824	190	199	220	215
Nutrition & Biosciences	\$ 4,557	\$ 1,467	\$ 1,539	\$ 1,551	\$ 6,076	\$ 1,458	\$ 1,525	\$ 1,558	\$ 1,535	\$ 6,216	\$ 1,485	\$ 1,533	\$ 1,621	\$ 1,577
Healthcare & Specialty	\$ 1,002	\$ 352	\$ 291	\$ 359	\$ 1,492	\$ 344	\$ 376	\$ 388	\$ 384	\$ 1,581	\$ 364	\$ 387	\$ 424	\$ 406
Industrial & Consumer	680	233	181	266	1,138	263	274	293	308	1,309	291	322	345	351
Mobility Solutions	1,339	460	360	519	2,320	548	559	588	625	2,532	615	648	648	621
Transportation & Industrial	\$ 3,021	\$ 1,045	\$ 832	\$ 1,144	\$ 4,950	\$ 1,155	\$ 1,209	\$ 1,269	\$ 1,317	\$ 5,422	\$ 1,270	\$ 1,357	\$ 1,417	\$ 1,378
Safety Solutions	\$ 1,746	\$ 534	\$ 581	\$ 631	\$ 2,549	\$ 597	\$ 630	\$ 657	\$ 665	\$ 2,483	\$ 613	\$ 619	\$ 639	\$ 612
Shelter Solutions	1,051	387	316	348	1,535	369	411	398	357	1,796	429	473	471	423
Water Solutions	972	328	347	297	1,117	284	286	286	261	1,015	252	272	262	229
Safety & Construction	\$ 3,769	\$ 1,249	\$ 1,244	\$ 1,276	\$ 5,201	\$ 1,250	\$ 1,327	\$ 1,341	\$ 1,283	\$ 5,294	\$ 1,294	\$ 1,364	\$ 1,372	\$ 1,264
Biomaterials	\$ 98	\$ 37	\$ 27	\$ 34	\$ 211	\$ 45	\$ 54	\$ 53	\$ 59	\$ 284	\$ 66	\$ 74	\$ 74	\$ 70
Clean Technologies	175	48	67	60	278	59	78	76	65	301	77	71	79	74
DuPont Teijin Films	124	47	34	43	172	45	48	42	37	198	49	51	51	47
Photovoltaic & Advanced Materials ¹	608	199	180	229	962	255	223	230	254	1,085	259	255	283	288
Sustainable Solutions ²	-	-	-	-	108	-	28	41	39	159	47	38	39	35
Non-Core	\$ 1,005	\$ 331	\$ 308	\$ 366	\$ 1,731	\$ 404	\$ 431	\$ 442	\$ 454	\$ 2,027	\$ 498	\$ 489	\$ 526	\$ 514
Total	\$ 15,145	\$ 5,096	\$ 4,828	\$ 5,221	\$ 21,512	\$ 5,204	\$ 5,426	\$ 5,468	\$ 5,414	\$ 22,594	\$ 5,457	\$ 5,683	\$ 5,857	\$ 5,597

1. The TCS business within Photovoltaic & Advanced Materials was divested in the third quarter of 2020.

2. Divested in the third quarter of 2019.

DuPont de Nemours, Inc.
Non-GAAP Free Cash Flow

	YTD 2020
<i>In millions</i>	<i>As Reported</i>
Cash Flow from Operations (GAAP)	\$ 2,794
Capital Expenditures	(922)
Free Cash Flow (non-GAAP)	\$ 1,872
Net (Loss) Income from continuing operations, net of tax (GAAP)	\$ (3,153)
Less: Gain on Non-Core divestitures ¹	334
Less: Goodwill impairments	(3,214)
Less: Asset impairments ¹	(503)
Less: Merger-related amortization ¹	(1,101)
Adjusted net income (non-GAAP)	\$ 1,331
Free Cash Flow Conversion	141%

1. Calculation on an after-tax basis